Europe Neurotoxins Market
Europe Neurotoxins Market is growing at a CAGR of 11.7% to reach US$ 2,038.94 million by 2028 from US$ 1,174.94 million in 2022 by Product Type, Application, and End User.

Published On: Jul 2023

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Europe Neurotoxins Market

At 11.7% CAGR, the Europe Neurotoxins Market is projected to be worth US$ 2,038.94 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Europe neurotoxins market was valued at US$ 1,174.94 million in 2023 and is expected to reach US$ 2,038.94 million by 2028, registering a CAGR of 11.7% from 2023 to 2028. Emergence of innovative facial aesthetic products and surge in cosmetic procedures to improve appearance are the critical factors attributed to the Europe neurotoxins market expansion.

The overall market for neurotoxins is expected to propel exponentially during the forecast period to meet the growing demand for facial aesthetics. In March 2022, Aquavit Pharmaceuticals, Inc. announced the submission of an Investigational New Drug (IND) of "DTX-021"—a botulinum toxin type A intended to treat moderate to severe glabellar lines. The product is a highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. By this technique, the contraction of the stomach muscles is restrained. Due to the limitation, the stomach's evacuation process takes longer, which causes the patient to feel full for longer period, resulting in reduced appetite and improved weight-related health issues/lifestyle disorders such as high blood pressure and diabetes mellitus. Therefore, emergence of innovative facial aesthetic products helps the Europe neurotoxin market to grow.  

On the contrary, improper/inappropriate injection technique hurdles the growth of Europe neurotoxins market

Based on product type, the Europe neurotoxins market is segmented into botox, dysport, xenomin, and others. The botox segment held 57.1% market share in 2023, amassing US$ 671.11 million. It is projected to garner US$ 1,142.78 million by 2028 to expand at 11.2% CAGR during 2023–2028.

Based on application, the Europe neurotoxins market is segmented into therapeutic and aesthetic. The therapeutic segment held 50.6% market share in 2023, amassing US$ 594.35 million. It is projected to garner US$ 1,022.89 million by 2028 to expand at 11.5% CAGR during 2023–2028.

Based on end user, the Europe neurotoxins market is segmented into hospitals, specialty clinics, dermatology clinics, and others. The hospitals segment held 52.4% market share in 2023, amassing US$ 615.33 million. It is projected to garner US$ 1,075.84 million by 2028 to expand at 11.8% CAGR during 2023–2028.

Based on country, the Europe neurotoxins market has been categorized into UK, Germany, France, Italy, Spain, Poland, Russia, and the Rest of Europe.  Our regional analysis states that Germany captured 22.4% market share in 2023. It was assessed at US$ 263.64 million in 2023 and is likely to hit US$ 470.99 million by 2028, exhibiting a CAGR of 12.3% during the forecast period.     

Key players dominating the Europe neurotoxins market are AbbVie Inc, Evolus Inc, Hugel Inc, Ipsen SA, Medytox Inc, and Merz Pharma GmbH & Co KGaA among others.

  • In Jan-2023, Hugel America, Inc. Announces Successful Completion of Croma-Pharma’s Decentralized Procedure for Letybo (LetibotulinumtoxinA Injection) in Europe. Approval is supported by positive results from three completed randomized, placebo-controlled phase III trials that enrolled more than 1000 subjects in Europe.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com